Abstract: In one embodiment, an automatic high-speed X-ray system may generate a high-resolution X-ray image of an inspected sample at a direction substantially orthogonal to a plane of the inspected sample. The system may determine a first cross-sectional shape of a first portion of a first element of interest in the inspected sample based on grayscale values of the X-ray image associated with the first element of interest. The system may determine a second cross-sectional shape of a second portion of the first element of interest in the inspected sample. The second cross-sectional shape may be determined based on the grayscale values of the X-ray image associated with the first element of interest. The system may determine one or more first metrological parameters associated with the first element of interest in the inspected sample based a comparison of the first cross-sectional shape and the second cross-sectional shape.

Abstract: In one embodiment, an automatic high-speed X-ray system may generate a high-resolution X-ray image of an inspected sample at a direction substantially orthogonal to a plane of the inspected sample. The system may determine a first cross-sectional shape of a first portion of a first element of interest in the inspected sample based on grayscale values of the X-ray image associated with the first element of interest. The system may determine a second cross-sectional shape of a second portion of the first element of interest in the inspected sample. The second cross-sectional shape may be determined based on the grayscale values of the X-ray image associated with the first element of interest. The system may determine one or more first metrological parameters associated with the first element of interest in the inspected sample based a comparison of the first cross-sectional shape and the second cross-sectional shape.

Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.

Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.

Abstract: The invention concerns a pellet for immediate release of an active substance to be ingested, said pellet comprising at least one active substance, a binding agent and a diluting agent, characterised in that said binding agent: comprises a mixture of glycerides subjected to polyglycolysis whereof the fatty acids comprise at least 8 carbon atoms; has a melting point not less than 37° C.; has a hydrophilic/lipophilic balance not less than 10, said binding agent being capable of enhancing the active substance bioavailability.

Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant.

Abstract: The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder mixture containing at least the active principle; subjecting said treated powder to a compressing step, to obtain tablets.

Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant. This process is characterized in that: a powder composed of at least one component selected in the group comprising the active principle and the adjuvant, is mixed, while heating and fluidizing, in order to obtain individual grains; the said lipid matrix agent is liquefied separately under warm conditions; the said powder is then coated under warm conditions by spraying the said lipid matrix agent over the individual grains; finally, the temperature of the combined product is lowered in order to allow the lipid matrix agent to solidify.

Abstract: Composition for pharmaceutical or cosmetic use, capable of providing enhanced bioavailability when ingested, comprising at least a pharmaceutical active ingredient, a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, a surfactant (SA), and a cosurfactant (CoSA). The lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 32 to 75% of the total weight of the composition. The surfactant (SA) is chosen from the group comprising saturated C8-C10 polyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16. The cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol. The SA/CoSA ratio is between 0.5 and 6 and the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.

Abstract: The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder mixture containing at least the active principle; subjecting said treated powder to a compressing step, to obtain tablets.

Abstract: The invention concerns a method for preparing a modified release of active principle. The method comprises the steps of mixing a powder composed of active principle, adjuvant or combinations thereof while heating and fluidizing in order to obtain individual grains, liquefying a lipid matrix agent composed of partial esters of alcohol with at least one fatty acid, coating the powder by spraying from 1 to 15% by weight of the final composition liquid lipid matrix agent over the individual grains, the spraying air pressure, and optionally the spraying rate varying throughout the coating operation and lowering the temperature of the combined product to allow the lipid matrix agent to solidify around the grains.

Abstract: Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least:an active principle,a lipophilic phase consisting of a mixture of fatty acid esters and glycerides,a surfactant (SA),a cosurfactant (CoSA),a hydrophilic phase,characterized:in that the lipophilic phase consists of a mixture of C.sub.8 to C.sub.18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition;in that the surfactant (SA) is chosen from the group comprising saturated C.sub.8 -C.sub.10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16;in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol;in that the SA/CoSA ratio is between 0.